Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts
Drost, FJH
Nieboer, D
Morgan, TM
Carroll, PR
Roobol, MJ
Trock, B
Ehdaie, B
Carroll, P
Filson, C
Kim, J
Logothetis, C
Morgan, T
Klotz, L
Pickles, T
Hyndman, E
Moore, CM
Gnanapragasam, V
Van Hemelrijck, M
Dasgupta, P
Bangma, C
Roobol, M
Villers, A
Rannikko, A
Valdagni, R
Perry, A
Hugosson, J
Rubio-Briones, J
Bjartell, A
Hefermehl, L
Shiong, LL
Frydenberg, M
Kakehi, Y
Chung, BH
van der Kwast, T
van der Linden, W
Hulsen, T
de Jonge, C
Kattan, M
Xinge, J
Muir, K
Lophatananon, A
Fahey, M
Steyerberg, E
Zhang, L
Beckmann, K
Denton, B
Hayen, A
Boutros, P
Guo, W
Benfante, N
Cowan, J
Patil, D
Tolosa, E
Kim, TK
Mamedov, A
Lapointe, V
Crump, T
Kimberly-Duffell, J
Santaolalla, A
Olivier, J
Rancati, T
Ahlgren, H
Mascarós, J
Löfgren, A
Lin, CH
Hirama, H
Lee, KS
Jenster, G
Auvinen, A
Haider, M
van Bochove, K
Carter, B
Gledhill, S
Buzza, M
Bruinsma, S
Helleman, J
- Publication Type:
- Journal Article
- Citation:
- European Urology, 2019, 76 (5), pp. 693 - 702
- Issue Date:
- 2019-11-01
Closed Access
Filename | Description | Size | |||
---|---|---|---|---|---|
1-s2.0-S0302283819306025-main.pdf | Published Version | 1.57 MB | Adobe PDF |
Copyright Clearance Process
- Recently Added
- In Progress
- Closed Access
This item is closed access and not available.
Full metadata record
Field | Value | Language |
---|---|---|
dc.contributor.author | Drost, FJH | en_US |
dc.contributor.author | Nieboer, D | en_US |
dc.contributor.author | Morgan, TM | en_US |
dc.contributor.author | Carroll, PR | en_US |
dc.contributor.author | Roobol, MJ | en_US |
dc.contributor.author | Trock, B | en_US |
dc.contributor.author | Ehdaie, B | en_US |
dc.contributor.author | Carroll, P | en_US |
dc.contributor.author | Filson, C | en_US |
dc.contributor.author | Kim, J | en_US |
dc.contributor.author | Logothetis, C | en_US |
dc.contributor.author | Morgan, T | en_US |
dc.contributor.author | Klotz, L | en_US |
dc.contributor.author | Pickles, T | en_US |
dc.contributor.author | Hyndman, E | en_US |
dc.contributor.author | Moore, CM | en_US |
dc.contributor.author | Gnanapragasam, V | en_US |
dc.contributor.author | Van Hemelrijck, M | en_US |
dc.contributor.author | Dasgupta, P | en_US |
dc.contributor.author | Bangma, C | en_US |
dc.contributor.author | Roobol, M | en_US |
dc.contributor.author | Villers, A | en_US |
dc.contributor.author | Rannikko, A | en_US |
dc.contributor.author | Valdagni, R | en_US |
dc.contributor.author | Perry, A | en_US |
dc.contributor.author | Hugosson, J | en_US |
dc.contributor.author | Rubio-Briones, J | en_US |
dc.contributor.author | Bjartell, A | en_US |
dc.contributor.author | Hefermehl, L | en_US |
dc.contributor.author | Shiong, LL | en_US |
dc.contributor.author | Frydenberg, M | en_US |
dc.contributor.author | Kakehi, Y | en_US |
dc.contributor.author | Chung, BH | en_US |
dc.contributor.author | van der Kwast, T | en_US |
dc.contributor.author | van der Linden, W | en_US |
dc.contributor.author | Hulsen, T | en_US |
dc.contributor.author | de Jonge, C | en_US |
dc.contributor.author | Kattan, M | en_US |
dc.contributor.author | Xinge, J | en_US |
dc.contributor.author | Muir, K | en_US |
dc.contributor.author | Lophatananon, A | en_US |
dc.contributor.author | Fahey, M | en_US |
dc.contributor.author | Steyerberg, E | en_US |
dc.contributor.author | Zhang, L | en_US |
dc.contributor.author | Beckmann, K | en_US |
dc.contributor.author | Denton, B | en_US |
dc.contributor.author |
Hayen, A |
en_US |
dc.contributor.author | Boutros, P | en_US |
dc.contributor.author | Guo, W | en_US |
dc.contributor.author | Benfante, N | en_US |
dc.contributor.author | Cowan, J | en_US |
dc.contributor.author | Patil, D | en_US |
dc.contributor.author | Tolosa, E | en_US |
dc.contributor.author | Kim, TK | en_US |
dc.contributor.author | Mamedov, A | en_US |
dc.contributor.author | Lapointe, V | en_US |
dc.contributor.author | Crump, T | en_US |
dc.contributor.author | Kimberly-Duffell, J | en_US |
dc.contributor.author | Santaolalla, A | en_US |
dc.contributor.author | Olivier, J | en_US |
dc.contributor.author | Rancati, T | en_US |
dc.contributor.author | Ahlgren, H | en_US |
dc.contributor.author | Mascarós, J | en_US |
dc.contributor.author | Löfgren, A | en_US |
dc.contributor.author | Lin, CH | en_US |
dc.contributor.author | Hirama, H | en_US |
dc.contributor.author | Lee, KS | en_US |
dc.contributor.author | Jenster, G | en_US |
dc.contributor.author | Auvinen, A | en_US |
dc.contributor.author | Haider, M | en_US |
dc.contributor.author | van Bochove, K | en_US |
dc.contributor.author | Carter, B | en_US |
dc.contributor.author | Gledhill, S | en_US |
dc.contributor.author | Buzza, M | en_US |
dc.contributor.author | Bruinsma, S | en_US |
dc.contributor.author | Helleman, J | en_US |
dc.date.available | 2019-07-24 | en_US |
dc.date.issued | 2019-11-01 | en_US |
dc.identifier.citation | European Urology, 2019, 76 (5), pp. 693 - 702 | en_US |
dc.identifier.issn | 0302-2838 | en_US |
dc.identifier.uri | http://hdl.handle.net/10453/137457 | |
dc.description.abstract | © 2019 European Association of Urology Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings. | en_US |
dc.relation.ispartof | European Urology | en_US |
dc.relation.isbasedon | 10.1016/j.eururo.2019.07.041 | en_US |
dc.rights | info:eu-repo/semantics/closedAccess | |
dc.subject.classification | Urology & Nephrology | en_US |
dc.title | Predicting Biopsy Outcomes During Active Surveillance for Prostate Cancer: External Validation of the Canary Prostate Active Surveillance Study Risk Calculators in Five Large Active Surveillance Cohorts | en_US |
dc.type | Journal Article | |
utslib.citation.volume | 5 | en_US |
utslib.citation.volume | 76 | en_US |
utslib.for | 1112 Oncology and Carcinogenesis | en_US |
utslib.for | 1103 Clinical Sciences | en_US |
pubs.embargo.period | Not known | en_US |
pubs.organisational-group | /University of Technology Sydney | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health | |
pubs.organisational-group | /University of Technology Sydney/Faculty of Health/Public Health | |
utslib.copyright.status | closed_access | * |
pubs.issue | 5 | en_US |
pubs.publication-status | Published | en_US |
pubs.volume | 76 | en_US |
Abstract:
© 2019 European Association of Urology Two active surveillance risk calculators to predict disease reclassification on prostate biopsy are externally validated by the Movember Foundation's Global Action Plan (GAP3) consortium. They proved to be clinically useful and could reduce unnecessary biopsies, but need recalibration to local settings.
Please use this identifier to cite or link to this item:
Download statistics for the last 12 months
Not enough data to produce graph